Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: Technical and microbiological aspects

Digestive Diseases and Sciences

Volumn 51, Issue 2, 2006, Pages 390-400

  Foligné, Benoit ^a   Nutten, Sophie ^a   Steidler, Lothar ^b,c   Dennin, Véronique ^a   Goudercourt, Denise ^a   Mercenier, Annick ^a   Pot, Bruno ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Inflammatory bowel disease; Probiotics; Standardization; Strain evaluation; TNBS mice model

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; INTERLEUKIN 10; NCIMB 8826; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL INFECTION; FEMALE; INFECTION PREVENTION; LACTIC ACID BACTERIUM; LACTOBACILLUS PLANTARUM; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; VALIDATION STUDY; WILD TYPE;

ANIMALS; COLITIS; DISEASE MODELS, ANIMAL; FEMALE; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; PROBIOTICS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TRINITROBENZENESULFONIC ACID;

EID: 33644899950     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-3143-x     Document Type: Article

References (53)

1. Chandran P, Satthaporn S, Robins A, Eremin O: Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II). Surgeon 3:125-136, 2003
2. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Scholmerich J, Sartor RB: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 69:2277-2285, 2001
3. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, Sartor RB:Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8:71-80, 2002
4. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN: Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116:1107-1114, 1999
5. Guarner F, Malagelada JR: Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol 17:793-804, 2003
6. Cong Y, Konrad A, Iqbal N, Elson CO: Probiotics and immune regulation of inflammatory bowel diseases. Curr Drug Targets Inflamm Allergy 2:145-154, 2003
7. Fedorak RN, Madsen KL: Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286-299, 2004
8. Strober W: Epithelial cells pay a Toll for protection. Nat Med 10:898-900, 2004
9. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126:520-528, 2004
10. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrissey D, O'Halloran S, Feeney M, Flynn S, Fitzgerald G, Daly C, Kiely B, O'Sullivan GC, Shanahan F, Collins JK: In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr Suppl 73:386-392, 2001
11. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F: Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52:975-980, 2003
12. Shanahan F: Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr Suppl 88:5-9, 2002
13. Hart AL, Stagg AJ, Kamm MA: Use of probiotics in the treatment of inflammatory bowel disease J Clin Gastroenterol 36:111-119, 2003
14. Gionchetti P, Amadini C, Rizzello F, Venturi A, Palmonari V, Morselli C, Romagnoli R, Campieri M: Probiotics role in inflammatory bowel disease. Dig Liver Dis 34:58-62, 2002
15. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, Koide Y: Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123:1912-1922, 2002
16. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290, 1995
17. Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495-549, 2002
18. Pizarro TT, Arseneau KO, Bamias G, Cominelli F: Mouse models for the study of Crohn's disease. Trends Mol Med 9:218-222, 2003
19. Fiorucci S, Antonelli E, Distrutti E, Del Soldato P, Flower RJ, Clark MJ, Morelli A, Perretti M, Ignarro LJ: NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci USA 99:15770-15775, 2002
20. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S: Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41:487-493, 1997
21. Cherbut C, Michel C, Lecannu G: The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr 133:21-27, 2003
22. Holma R, Salmenpera P, Lohi J, Vapaatalo H, Korpela R: Effects of Lactobacillus rhamnosus GG and Lactobacillus reuteri R2LC on acetic acid-induced colitis in rats. Scand J Gastroenterol 36:630-635, 2001
23. Kennedy RJ, Hoper M, Deodhar K, Kirk SJ, Gardiner KR: Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scand J Gastroenterol 35:1266-1271, 2000
24. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305-309, 2000
25. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E: Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122:1428-1441, 2002
26. Obermeier F, Dunger N, Strauch UG, Grunwald N, Herfarth H, Scholmerich J, Falk W: Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol 134:217-224, 2003
27. Pathmakanthan S, Li CK, Cowie J, Hawkey CJ: Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 19:166-173, 2004
28. Sanders ME: Probiotics. Food Technol 53:67-75, 1999
29. Molin G: Probiotics in foods not containing milk or milk constituents, with special reference to Lactobacillus plantarum 299v. Am J Clin Nutr Suppl 73:380-385, 2001
30. Cebeci A and Gürakan C: Properties of potential probiotic Lactobacillus plantarum strains. Food Microbiol 20:511-518, 2003
31. Muller-Alouf H, Grangette C, Goudercourt D, Reveneau N, Mercenier A: Comparative cytokine inducing pattern of lactic acid bacteria used for mucosal vaccine development. Immunol Lett 69:33, 1999
32. Vesa T, Pochart P, Marteau P: Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 14:823-828, 2000
33. Pavan S, Desreumaux P, Mercenier A: Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol 10:696-701, 2003
34. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352-1355, 2000
35. Schotte L, Steidler L, Vandekerckhove J, Remaut E: Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 10:761-765, 2000
36. Wallace JL, MacNaughton WK, Morris GP, Beck PL: Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29-36, 1989
37. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J: Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193:827-838, 2001
38. Lindsay J, Van Montfrans C, Brennan F, Van Deventer S, Drillenburg P, Hodgson H, Te Velde A, Sol Rodriguez Pena M: IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther 9:1715-1721, 2002
39. Campos FG, Waitzberg DL, Logulo AF, Cukier C, Soares SR, Oliveira TS, Torrinhas RS, Plopper C, Terra RM, Lotierzo PH, Habr-Gama A: Technical and histological standardization of experimental colitis with trinitrobenzenosulfonic acid (TNBS). Rev Hosp Clin Fac Med Sao Paulo 52:180-186, 1997
40. Mahler M, Bristol IJ, Leiter EH, Workman AE, Birkenmeier EH, Elson CO, Sundberg JP: Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 274:544-551, 1998
41. Savendahl L, Underwood LE, Haldeman KM, Ulshen MH, Lund PK: Fasting prevents experimental murine colitis produced by dextran sulfate sodium and decreases interleukin-1 beta and insulin-like growth factor I messenger ribonucleic acid. Endocrinology 138:734-740, 1997
42. Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ: Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 52:363-369, 2003
43. Corazza N, Eichenberger S, Eugster HP, Mueller C: Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med 190:1479-1492, 1999
44. Waidmann M, Bechtold O, Frick JS, Lehr HA, Schubert S, Dobrindt U, Loeffler J, Bohn E, Autenrieth IB: Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 125:162-177, 2003
45. Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF, Granger DN: Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 49:556-564, 2004
46. Gardiner KR, Erwin PJ, Anderson NH, Barr JG, Halliday MI, Rowlands BJ: Colonic bacteria and bacterial translocation in experimental colitis. Br J Surg 80:512-516, 1993
47. Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, Campieri M, Morgenstern S, Rachmilewitz D: Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 8:399-406, 2002
48. Osman N, Adawi D, Ahrne S, Jeppsson B, Molin G: Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci 49:320-327, 2004
49. Castagliuolo I, Galeazzi F, Ferrari S, Elli M, Brun P, Cavaggioni A, Tormen D, Sturniolo GC, Morelli L, Palu G. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol Med Microbiol 43:197-204, 2005
50. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702, 1990
51. Ishizuka K, Sugimura K, Homma T, Matsuzawa J, Mochizuki T, Kobayashi M, Suzuki K, Otsuka K, Tashiro K, Yamaguchi O, Asakura H. Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion 63:22-27, 2001
52. Elson CO: Experimental models if intestinal inflammation: new insights into mechanisms of mucosal homeostasis. In Mucosal Immunology.Ogro PL, Lamm ME, Bienenstock J, et al. (eds). San Diego, CA, Academic Press, 1999, pp 1007-1024
53. Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M: Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 133:38-43, 2003